Capstone (NASDAQ:CAPS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Capstone (NASDAQ:CAPS) to a sell rating in a research report report published on Friday.

Capstone Stock Down 2.1%

NASDAQ CAPS opened at $1.86 on Friday. The stock’s fifty day moving average price is $2.03. Capstone has a 52 week low of $1.58 and a 52 week high of $16.18.

Capstone Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.